11:09 , Apr 16, 2019 |  BioCentury  |  Emerging Company Profile

Kintai’s host-targeting niche in Flagship microbiome ecosystem

Kintai, Flagship’s latest foray into microbiome-based medicines, is taking bugs out of the equation by developing oral small molecules that mimic microbes’ therapeutic effects. Emerging from stealth mode Tuesday and led by Paul-Peter Tak as...
07:00 , Oct 26, 2015 |  BioCentury  |  Strategy

Collaborating on combos

As oncologists and drug developers converge on the idea that combination therapies built on a backbone of PD-L1 or PD-1 inhibitors could lead to cures for some cancers, or keep them at bay for years,...
07:00 , May 8, 2006 |  BC Week In Review  |  Clinical News

BT Test: Pilot trial started

Biomarker started a pilot trial for the early detection of breast cancer through cancer-related biomarkers. Biomarker will collect blood samples from about 505 women referred for biopsy, 125 referred for other types of cancer and...
08:00 , Mar 13, 2006 |  BC Week In Review  |  Clinical News

BT Test update

Biomarker will begin this month a trial to detect breast cancer through cancer-related biomarkers. Biomarker will collect blood samples from 430 women referred for biopsy, 125 referred for other types of cancer and 300 healthy...
08:00 , Mar 28, 2005 |  BC Week In Review  |  Clinical News

BT Test: Pilot trial start

Biomarker will begin next month a U.S. pilot study in 100 subjects. The study will be a retrospective blind test with samples from healthy subjects, breast cancer patients and patients with other cancer conditions. Biomarker...